Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer

NCT02929797 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

BIOLOGICAL: CD8+NKG2D+ AKT Cell
DRUG: Gemcitabine

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Collaborators

[object Object]